Yesterday, the Executive VP and CFO of Palatin Technologies Inc (PTN), Stephen Wills, bought shares of PTN for $43K.
In addition to Stephen Wills, 2 other PTN executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Palatin Technologies Inc has an average volume of 2.4M. The Company has a Price to Book ratio of 9.8622.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $5.75, reflecting a 636.9% upside. Starting in September 2018, PTN received 12 Buy ratings in a row. Three different firms, including Canaccord Genuity and Ladenburg Thalmann & Co., currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
